GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aura Biosciences Inc (NAS:AURA) » Definitions » Shares Outstanding (EOP)

AURA (Aura Biosciences) Shares Outstanding (EOP) : 49.78 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aura Biosciences Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Aura Biosciences's shares outstanding for the quarter that ended in Sep. 2024 was 49.78 Mil.

Aura Biosciences's quarterly shares outstanding increased from Jun. 2024 (49.58 Mil) to Sep. 2024 (49.78 Mil). It means Aura Biosciences issued new shares from Jun. 2024 to Sep. 2024 .

Aura Biosciences's annual shares outstanding increased from Dec. 2022 (37.77 Mil) to Dec. 2023 (49.35 Mil). It means Aura Biosciences issued new shares from Dec. 2022 to Dec. 2023 .


Aura Biosciences Shares Outstanding (EOP) Historical Data

The historical data trend for Aura Biosciences's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aura Biosciences Shares Outstanding (EOP) Chart

Aura Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
13.89 19.57 29.21 37.77 49.35

Aura Biosciences Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.22 49.35 49.50 49.58 49.78

Competitive Comparison of Aura Biosciences's Shares Outstanding (EOP)

For the Biotechnology subindustry, Aura Biosciences's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aura Biosciences's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aura Biosciences's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Aura Biosciences's Shares Outstanding (EOP) falls into.



Aura Biosciences Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Aura Biosciences  (NAS:AURA) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Aura Biosciences Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Aura Biosciences's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Aura Biosciences Business Description

Traded in Other Exchanges
N/A
Address
80 Guest Street, Boston, MA, USA, 02135
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Executives
Janet Jill Hopkins officer: See Remarks C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON MA 01235
De Los Pinos Elisabet director, officer: Chief Executive Officer C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Julie B Feder officer: Chief Financial Officer C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Matrix Capital Management Company, Lp 10 percent owner 1000 WINTER STREET, C/O MATRIX CAPITAL MANAGEMENT, WALTHAM MA 02451
David Michael Johnson director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Cadmus Rich officer: See Remarks C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Rosch Mark De officer: Chief Operating Officer C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Ventures Management (jersey) Ltd 10 percent owner C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth I Lp 10 percent owner C/O ELIAN FUND SERVICES (JERSEY) LIMITED, 44 ESPLANADE, ST HELIER Y9 JE4 9WG
Giovanni Mariggi director C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Growth I Gp Ltd 10 percent owner C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth Co-invest I Lp 10 percent owner C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
David E. Goel 10 percent owner C/O MATRIX CAPITAL MANAGEMENT CO., LP, 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Karan S. Takhar director C/O ZENTALIS PHARMACEUTICALS,INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Antony C. Mattessich director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730